Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex.Franklin, M.C., Carey, K.D., Vajdos, F.F., Leahy, D.J., De Vos, A.M., Sliwkowski, M.X.
(2004) Cancer Cell 5: 317-328
- PubMed: 15093539
- DOI: 10.1016/s1535-6108(04)00083-2
- Primary Citation of Related Structures:
- PubMed Abstract:
- Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
Cho, H.S., Mason, K., Ramyar, K.X., Stanley, A.M., Gabelli, S.B., Denney Jr., D.W., Leahy, D.J.
(2003) Nature 421: 756
- Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis
Vajdos, F.F., Adams, C.W., Breece, T.N., Presta, L.G., de Vos, A.M., Sidhu, S.S.
(2002) J Mol Biol 320: 415
- Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
Agus, D.B., Akita, R.W., Fox, W.D., Lewis, G.D., Higgins, B., Pisacane, P.I., Lofgren, J.A., Tindell, C., Evans, D.P., Maiese, K., Scher, H.I., Sliwkowski, M.X.
(2002) Cancer Cell 2: 127
We have determined the 3.2 A X-ray crystal structure of the extracellular domain of the human epidermal growth factor receptor 2 (ErbB2 or HER2) in a complex with the antigen binding fragment of pertuzumab, an anti-ErbB2 monoclonal antibody also know ...
We have determined the 3.2 A X-ray crystal structure of the extracellular domain of the human epidermal growth factor receptor 2 (ErbB2 or HER2) in a complex with the antigen binding fragment of pertuzumab, an anti-ErbB2 monoclonal antibody also known as 2C4 or Omnitarg. Pertuzumab binds to ErbB2 near the center of domain II, sterically blocking a binding pocket necessary for receptor dimerization and signaling. The ErbB2-pertuzumab structure, combined with earlier mutagenesis data, defines the pertuzumab residues essential for ErbB2 interaction. To analyze the ErbB2 side of the interface, we have mutated a number of residues contacting pertuzumab and examined the effects of these mutations on pertuzumab binding and ErbB2-ErbB3 heterodimerization. We have also shown that conserved residues previously shown to be necessary for EGF receptor homodimerization may be dispensible for ErbB2-ErbB3 heterodimerization.
Department of Protein Engineering, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94114 USA.